Nuclera, a biotechnology company, has entered a collaboration with Cytiva, a global life sciences leader, to accelerate the production, purification and characterization of proteins required for drug research and development. The partnership will leverage both Nuclera’s eProtein Discovery System and Cytiva’s Biacore surface plasmon resonance (SPR) technology.

Proteins represent 95% of drug targets designed to combat disease. Rapid access to these proteins and understanding how they interact with drug candidates is essential for drug development. Typically, it takes months to obtain and characterize proteins, but Nuclera and Cytiva together have achieved production and characterization within five days.

Dr. Yvonne Tan, Associate Director of Product Management, Nuclera, commented: “Collaborating with life science leader Cytiva supports Nuclera in our mission of improving human health. Through this collaboration, we have demonstrated eProtein Discovery’s ability to produce clinically significant proteins that can be used in characterization experiments. Combining eProtein Discovery’s capability to streamline protein production workflows with Cytiva’s Biacore protein characterization systems opens a whole new avenue for accelerating drug development.”

Anna Moberg, Senior Manager and Project Manager, Cytiva, added: “The ability of Nuclera’s eProtein Discovery to accelerate protein production and purification complements Cytiva’s Biacore SPR technology by streamlining the upstream protein production process. We look forward to continuing our collaboration to further enhance the production of characterizable proteins for drug development.”